High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia

Lee,Ji  Yoon; Park,Sohye; Han,A-Reum; Lim,Jihyang; Min,Woo-Sung; Kim,Hee-Je

doi:10.3892/or.2014.3359

High ALDHdim-expressing CD34+CD38- cells in leukapheresed peripheral blood is a reliable guide for a successful leukemic xenograft model of acute myeloid leukemia

Authors:
- Ji Yoon Lee
- Sohye Park
- A-Reum Han
- Jihyang Lim
- Woo-Sung Min
- Hee-Je Kim
View Affiliations

Affiliations: Cancer Research Institute, Department of Hematology, Catholic Blood and Marrow Transplantation Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea, Laboratory Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Published online on: July 24, 2014 https://doi.org/10.3892/or.2014.3359
Pages: 1638-1646

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The primary human acute myeloid leukemia (AML) cell injection xenograft mouse model is used to investigate multimodal therapies and drug screening on tumor growth. Since xenograft models using human cell lines to examine drug response are not correlated with the clinical outcomes observed in patients, a xenograft model using primary human cells has been used as a more appropriate model with which to minimize this problem. Although bone marrow (BM) cells from patients are often regarded as superior sources to establish xenograft models due to the high frequency of stem cell populations, there is a fatal drawback; only small volumes can be obtained and used for the generation of the leukemic xenograft model. Indeed, longevity of AML characteristics, as well as sufficient stem cells in the xenograft model, should be guaranteed to analyze the therapeutic response to a drug. Therefore, we examined whether leukapheresed peripheral blood (LPB) consists of reliable leukemic stem cells (LSCs) and ALDHdim‑expressing CD34+CD38- cells, and functions in grafting human AML with virulence compared to that of BM. LPB cells showed an advantage for the xenograft mouse model with AML cell homing, engraftment and a high human ALDHdim-expressing CD34+CD38- cell population, suggesting an alternative cell source to BM. Overall, this xenograft model using LPB offers the possibility of overcoming the small volume limitation of BM and prevents individual variation by using a single LPB sample. This result is noteworthy in identifying cell sources capable of generating a stable xenograft model.

View Figures

View References

1	Gopinathan A and Tuveson DA: The use of GEM models for experimental cancer therapeutics. Dis Model Mech. 1:83–86. 2012. View Article : Google Scholar
2	Richmond A and Su Y: Mouse xenograft models vs GEM models for human cancer therapeutics. Dis Model Mech. 1:78–82. 2008. View Article : Google Scholar : PubMed/NCBI
3	Kelland LR: Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 40:827–836. 2004.PubMed/NCBI
4	McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M and Weissman IL: The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science. 241:1632–1639. 1988. View Article : Google Scholar : PubMed/NCBI
5	Mosier DE, Gulizia RJ, Baird SM and Wilson DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature. 335:256–259. 1988. View Article : Google Scholar : PubMed/NCBI
6	Lubin I, Faktorowich Y, Lapidot T, Gan Y, Eshhar Z, Gazit E, et al: Engraftment and development of human T and B cells in mice after bone marrow transplantation. Science. 252:427–431. 1991. View Article : Google Scholar : PubMed/NCBI
7	Lapidot T, Pflumio F, Doedens M, Murdoch B, Williams DE and Dick JE: Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science. 255:1137–1141. 1992. View Article : Google Scholar : PubMed/NCBI
8	Cheung AM, Wan TS, Leung JC, Chan LY, Huang H, Kwong YL, et al: Aldehyde dehydrogenase activity in leukemic blasts defines a subgroup of acute myeloid leukemia with adverse prognosis and superior NOD/SCID engrafting potential. Leukemia. 21:1423–1430. 2007. View Article : Google Scholar
9	Ishikawa F, Yasukawa M, Lyons B, Yoshida S, Miyamoto T, Yoshimoto G, et al: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood. 106:1565–1573. 2005. View Article : Google Scholar : PubMed/NCBI
10	Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S, et al: Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 25:1315–1321. 2007. View Article : Google Scholar : PubMed/NCBI
11	Will B, Kawahara M, Luciano JP, Bruns I, Parekh S, Erickson-Miller CL, et al: Effect of the nonpeptide thrombo-poietin receptor agonist Eltrombopag on bone marrow cells from patients with acute myeloid leukemia and myelodysplastic syndrome. Blood. 114:3899–3908. 2009. View Article : Google Scholar : PubMed/NCBI
12	Sanchez PV, Perry RL, Sarry JE, Perl AE, Murphy K, Swider CR, et al: A robust xenotransplantation model for acute myeloid leukemia. Leukemia. 23:2109–2117. 2009. View Article : Google Scholar : PubMed/NCBI
13	Goardon N, Marchi E, Atzberger A, Quek L, Schuh A, Soneji S, et al: Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell. 19:138–152. 2011. View Article : Google Scholar : PubMed/NCBI
14	Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, et al: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 367:645–648. 1994. View Article : Google Scholar : PubMed/NCBI
15	Sarry JE, Murphy K, Perry R, Sanchez PV, Secreto A, Keefer C, et al: Human acute myelogenous leukemia stem cells are rare and heterogeneous when assayed in NOD/SCID/IL2Rγc-deficient mice. J Clin Invest. 121:384–395. 2011.PubMed/NCBI
16	Gerber JM, Smith BD, Ngwang B, Zhang H, Vala MS, Morsberger L, et al: A clinically relevant population of leukemic CD34(+)CD38(−) cells in acute myeloid leukemia. Blood. 119:3571–3577. 2012.PubMed/NCBI
17	Hong SH, Nah HY, Lee JY, Lee YJ, Lee JW, Gye MC, et al: Estrogen regulates the expression of the small proline-rich 2 gene family in the mouse uterus. Mol Cells. 17:477–484. 2004.PubMed/NCBI
18	Lee JY, Park C, Cho YP, Lee E, Kim H, Kim P, et al: Podoplanin-expressing cells derived from bone marrow play a crucial role in postnatal lymphatic neovascularization. Circulation. 122:1413–1425. 2010. View Article : Google Scholar : PubMed/NCBI
19	Shultz LD, Ishikawa F and Greiner DL: Humanized mice in translational biomedical research. Nat Rev Immunol. 7:118–130. 2007. View Article : Google Scholar : PubMed/NCBI
20	Choi B, Chun E, Kim M, Kim SY, Kim ST, Yoon K, et al: Human T cell development in the liver of humanized NOD/SCID/ IL-2Rγ(null)(NSG) mice generated by intrahepatic injection of CD34(+) human (h) cord blood (CB) cells. Clin Immunol. 139:321–335. 2011.PubMed/NCBI
21	Notta F, Doulatov S and Dick JE: Engraftment of human hematopoietic stem cells is more efficient in female NOD/SCID/ IL-2Rg_c-null recipients. Blood. 115:3704–3707. 2010. View Article : Google Scholar : PubMed/NCBI
22	Lacombe F, Durrieu F, Briais A, Dumain P, Belloc F, Bascans E, et al: Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia. 11:1878–1886. 1997. View Article : Google Scholar : PubMed/NCBI
23	Whartenby KA, Straley EE, Kim H, Racke F, Tanavde V, Gorski KS, et al: Transduction of donor hematopoietic stem-progenitor cells with Fas ligand enhanced short-term engraftment in a murine model of allogeneic bone marrow transplantation. Blood. 100:3147–3154. 2002. View Article : Google Scholar
24	Breems DA, van Hennik PB, Kusadasi N, Boudewijn A, Cornelissen JJ, Sonneveld P and Ploemacher RE: Individual stem cell quality in leukapheresis products is related to the number of mobilized stem cells. Blood. 87:5370–5378. 1996.PubMed/NCBI
25	Zhang J, Yang WH, Yang XD, Shi ZX, Wang XL, Yu WJ, et al: Establishment and identification of CML model via injection of K562 cells into the murine caudal vein. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 20:773–776. 2012.(In Chinese).
26	Park J, Kim KI, Koh Y, Won NH, Oh JM, Lee DS, et al: Establishment of a new Glivec-resistant chronic myeloid leukemia cell line, SNUCML-02, using an in vivo model. Exp Hematol. 38:773–781. 2010. View Article : Google Scholar : PubMed/NCBI
27	Lee J, Li M, Milwid J, Dunham J, Vinegoni C, Gorbatov R, et al: Implantable microenvironments to attract hematopoietic stem/cancer cells. Proc Natl Acad Sci USA. 109:19638–19643. 2012. View Article : Google Scholar : PubMed/NCBI
28	Elias AD, Ayash L, Anderson KC, Hunt M, Wheeler C, Schwartz G, et al: Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer. Blood. 79:3036–3044. 1992.